Tumor Recurrence
8
2
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
Ex-vivo Hypotermic Perfusion in Patients with Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence
HOPE to Reduce Tumour Recurrence After LT In Patients With HCC
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma